Skip to main content
. 2016 Aug 22;7(38):62327–62339. doi: 10.18632/oncotarget.11469

Figure 2. eIF5B up-regulation predicts aggressive clinicopathological characteristics and poor prognosis in patients with HCC.

Figure 2

A-C. Expression patterns of eIF5B in patients with HCC with high vs. low AFP levels, large vs. small tumors, and positive vs. negative vessel invasion (VI). D-E. Kaplan-Meier survival curves of recurrence-free survival (RFS) and overall survival (OS) in the cohort. Patients were assigned into one of two subgroups according to the median expression level of eIF5B (*P<0.05; **P<0.01).